Reflate tb study. Results of the ANRS 12 180 Reflate TB sub-study.

Reflate tb study. In this phase 3 trial, we assessed the non-inferiority of raltegravir to efavirenz. 20th Conference on Retroviruses and Opportunistic Infections. Mar 2, 2021 · To our knowledge, the Reflate TB 2 study is the only comparative, randomised, phase 3 trial to assess the efficacy of an integrase inhibitor-based antiretroviral regimen in the context of HIV and tuberculosis co-infection. May 14, 2025 · We conducted a secondary analysis of the ANRS 12300 Reflate TB2, an international phase III open-label randomized trial that assessed different antiretroviral regimens in PLWH treated for tuberculosis. Methods: We did a multicentre, open-label, non-inferiority, randomised, phase 3 trial at six sites in Côte d'Ivoire, Brazil, France, Mozambique, and Vietnam. Abstract 539. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis. Results of the ANRS 12 180 Reflate TB sub-study. Google To date, Reflate TB 2 has included the largest study population, enrolled in 4 countries, in a comparative trial that evaluated INSTI versus NNRTI-based ART in PWH with TB and collected standardized data from all IRIS cases. To our knowledge, the Reflate TB 2 study is the only phase 3 comparative randomized clinical trial assessing the efficacy of an integrase inhibitor based antiretroviral regimen in the context of HIV and tuberculosis co- infection. Jun 1, 2021 · To our knowledge, the Reflate TB 2 study is the only comparative, randomised, phase 3 trial to assess the efficacy of an integrase inhibitor-based antiretroviral regimen in the context of HIV and tuberculosis co-infection. Methods: We did a multicentre, phase 2, non-comparative, open-label, randomised trial at eight sites in Brazil and France. 1 Jan 22, 2024 · To date, Reflate TB 2 has included the largest study population, enrolled in 4 countries, in a comparative trial that evaluated INSTI versus NNRTI-based ART in PWH with TB and collected standardized data from all IRIS cases. Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis – a secondary analysis of the ANRS 12300 Reflate TB2 trial Added value of this study To our knowledge, the Reflate TB 2 study is the only comparative, randomised, phase 3 trial to assess the eficacy of an integrase inhibitor-based antiretroviral regimen in the context of HIV and tuberculosis co-infection. PubMed Google Scholar 23. Atlanta, GA, USA: March 3–6, 2013. Pharmacokinetics of two doses of raltegravir in combination with rifampin in HIV-TB co-infected patients. ANRS 12180 Reflate TB trial was a multicentre, open-label, randomized, phase II trial, where 153 ART-naïve PWH with tuberculosis from Brazil or France were randomised to receive raltegravir (400 or 800 mg twice daily) or efavirenz (600 mg once daily), in combination with tenofovir and lamivudine. . Mar 2, 2021 · The open-label, randomised, phase 3 ANRS 12 300 Reflate TB 2 study assessed the non-inferiority of integrase strand-transfer inhibitor (INSTI) raltegravir 400 mg twice daily to efavirenz in ART-naive patients within 2–8 weeks of commencing treatment for tuberculosis. Jan 11, 2020 · The ANRS 12180 REFLATE-TB trial was a phase II, multicenter, noncomparative, open-label, randomized study of the efficacy of 2 doses of RAL (400 mg or 800 mg BID) or EFV-based first-line ART to suppress viral replication in participants coinfected with HIV-1 and TB. Sauvageon H, Grinsztejn B, Arnold V, et al. y8v8k 3q2d dmryia 7h9e frpqa nyc ngvl oqob ggrvkrs qkio